BioCentury | Feb 13, 2021
Product Development

Argenx turning cash cow into global commercialization engine

...Phase II CULMINATE trial in combination with azacitidine...
...Phase I ELEVATE trial in combination with azacitidine...
BioCentury | Dec 31, 2020
Product Development

Dec. 30 Quick Takes: Approval for Sinopharm vaccine follows report of 79% protection; plus Aprea, Axsome, Serum Institute, Pfizer-BioNTech, Moderna, Inotrem and Actinium

...78% to $5.50 on Monday. The reactivator of mutant and inactivated TP53 plus azacitidine vs. azacitidine...
BioCentury | Nov 24, 2020
Product Development

ASH preview & long shot drug pricing rules: a BioCentury podcast

...their AML data and specifically pointing to how it might be the CD47 inhibitor plus azacitidine...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas for the IgG4 mAb magrolimab plus azacitidine...
BioCentury | Nov 11, 2020

Previewing CD47 efficacy data at SITC & ASH: Data Byte for the IgG4 mAb magrolimab plus azacitidine...
BioCentury | Oct 15, 2020
Product Development

Oct. 14 Quick Takes: FDA approves first Ebola therapy; plus Vertex tumbles after hours on AAT discontinuation

...III ASTRAL-3 study to treat myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia after failure of azacitidine...
BioCentury | Sep 2, 2020

Sept. 1 Quick Takes: House committee to subpoena AbbVie on pricing; plus Athenex, Harmony, AZ, BMS, Novo, and cancer trial guidance

...cell lung cancer in combination with select chemotherapies.FDA approves BMS’s Onureg for AMLFDA approved Onureg azacitidine...
BioCentury | Aug 4, 2020
Politics, Policy & Law

China doubling size of centralized procurement program

...antibiotic from Bayer AG (Xetra:BAYN); seizure drug Keppra levetiracetam from UCB S.A. (Euronext:UCB); and Vidaza azacitidine...
BioCentury | Jul 13, 2020

BeiGene’s billions to support new launches, deep pipeline well as two products from Bristol Myers Squibb Co. (NYSE:BMY): Revlimid lenalidomide and Vidaza azacitidine...
BioCentury | Jul 2, 2020
Product Development

July 1 Quick Takes: Amgen gains on court win; plus Hua, J&J, argenx, Seattle Genetics-Genmab, Interprotein

...a median age of 75, monotherapy with the anti-CD70 mAb followed by combination therapy with azacitidine...
Items per page:
1 - 10 of 372